Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies.

Ann Otol Rhinol LaryngolMay 28, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Open access

Ann Edmunds, Christine Bentley, Mark Lückermann et al.

✦ AI-curated · Sources linked

In 30 seconds

This study evaluated the efficacy and safety of finafloxacin otic suspension (0.3%) in treating acute otitis externa (AOE) in patients aged 6 months and older through two Phase III randomized controlled trials. Finafloxacin demonstrated a clinical cure rate of 70.2% compared to 36.6% for the vehicle group (P < .0001), indicating significant superiority in treating AOE.

Key findings

  • Finafloxacin achieved a clinical cure rate of 70.2% vs 36.6% in the vehicle group (P < .0001).
  • Median time to cessation of ear pain was 3.5 days for finafloxacin compared to 7.0 days for the vehicle (P < .0001).
  • Finafloxacin eradicated 89% of Staphylococcus aureus and 85.3% of Pseudomonas aeruginosa.
  • The safety profile of finafloxacin was comparable to that of the vehicle.

Why it matters

The findings suggest that finafloxacin otic suspension is an effective treatment option for acute otitis externa, particularly in eradicating common pathogens and reducing pain duration, which may improve patient outcomes.

Source

PubMed · PMID 42210509Free full text on PubMed Central

Published in Ann Otol Rhinol Laryngol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.